MABN1788
Anti-FMR1polyG Antibody, clone 9FM-1B7
ascites fluid, clone 9FM-1B7, from mouse
Synonym(s):
FMR1polyG, FMRpolyG, FMR1 RANT, FMR1 repeat-associated non-ATG-initiated translation, FMR1 repeat-associated non-AUG-initiated translation, Fragile X mental retardation protein 1 gene RANT
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
ascites fluid
antibody product type
primary antibodies
clone
9FM-1B7, monoclonal
species reactivity
human
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1κ
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... FRAXA(2477) , FRAXA(108684022)
General description
Fragile X-associated Tremor/Ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by an elevated CGG-repeat expansions (55-200) in the 5′ UTR of the fragile-X mental retardation 1 gene FMR1 (also known as FRAXA, POF1; Gene ID 2332) on the X-chromosome. The CGG repeat expansion in FXTAS triggers repeat-associated non-ATG-initiated translation (RAN or RANT), also known as repeat-associated non-AUG-initiated translation, within the 5’UTR of FMR1 mRNA, resulting in the production of fusion proteins (FMR1polyG) that contain N-terminal polyglycine fused to either C-terminal FMR1 in-frame sequence or one of two FMR1 frame-shift sequences. Immunohistochemical analysis of FXTAS brain tissues reveals FMR1polyG-positive aggregates that closely resemble neuronal intranuclear inclusions seen in polyglutamine diseases and other protein-mediated neurodegenerative disorders. Much larger expansions of the same repeat cause fragile X syndrome (FRAX), the most common inherited form of mental retardation, by silencing FMR1 transcription.
Specificity
This monoclonal antibody does not detect the Fragile X mental retardation protein 1 sequences reported by UniProt (Q06787-1 through Q06787-9). It detects one of the two possible types of FMR1 frame-shift sequences with N-terminal polyG fusion found in Fragile X-associated Tremor/Ataxia syndrome (FXTAS) patients due to CGG repeats expansion (55-200 repeats) in the 5’UTR of the FMR1 gene. Due to the extended aggregation of the pathological forms of FMR1polyG, the detection of FMR1polyG in patient samples by Western blotting is not recommended.
Immunogen
Epitope: C-terminal region.
Ovalbumin-conjugated linear peptide corresponding to a sequence from the C-terminal region of FMR1polyG.
Application
Anti-FMR1polyG Antibody, clone 9FM-1B7 is an antibody against FMR1polyG for use in Western Blotting, Immunohistochemistry.
Immunohistochemistry Analysis: A representative lot detected FMR1polyG immunoreactivity in paraffin-embedded brain tissue sections from an Fragile X-associated Tremor/Ataxia syndrome (FXTAS) patient, but not in brain tissues from non-FXTAS individuals (Buijsen, R.A., et al. (2014). Acta Neuropathol. Commun. 2:162).
Western Blotting Analysis: A representative lot detected an exogenously expressed FMR1polyG EGFP fusion construct corresponding to 5′UTR of FMR1 with 50 CGG repeats (Buijsen, R.A., et al. (2014). Acta Neuropathol. Commun. 2:162).
Western Blotting Analysis: A representative lot detected an exogenously expressed FMR1polyG EGFP fusion construct corresponding to 5′UTR of FMR1 with 50 CGG repeats (Buijsen, R.A., et al. (2014). Acta Neuropathol. Commun. 2:162).
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Quality
Evaluated by Western Blotting in GFP-FMR1polyG-expressing COS cell lysate.
Western Blotting Analysis: A 1:2,000 dilution of this antibody detected an exogenously expressed FMR1polyG GFP fusion construct in transfected COS cells.
Western Blotting Analysis: A 1:2,000 dilution of this antibody detected an exogenously expressed FMR1polyG GFP fusion construct in transfected COS cells.
Target description
Variable, depending on the sizes of the FMR1polyG fusions and aggregates.
Physical form
Mouse monoclonal IgG1κ antibody in ascites with 0.05% sodium azide.
Unpurified
Storage and Stability
Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Other Notes
Concentration: Please refer to lot specific datasheet.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service